순환종양핵산 검사의 임상 적용

Abstract

Liquid biopsy using circulating tumor DNA helps overcome the limitations of conventional tissue testing. Non-invasive molecular profiling using circulating tumor DNA is increasingly being used to diagnose cancer, stratify risk, and select targeted treatments. By understanding the biological characteristics of circulating tumor DNA and patient factors that can affect concentrations of circulating tumor DNA as well as optimizing the techniques, the clinical utilization of circulating tumor DNA tests can be improved. It is also necessary to formulate guidelines for the administration and reporting of circulating tumor DNA tests.